Get the Stockscreener App
1.94
3.96%
-0.08
After Hours:
1.98
0.04
+2.06%
Nervgen Pharma Corp stock is traded at $1.94, with a volume of 343.19K.
It is down -3.96% in the last 24 hours and down -6.73% over the past month.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.
See More
Previous Close:
$2.02
Open:
$2
24h Volume:
343.19K
Relative Volume:
0.56
Market Cap:
$208.59M
Revenue:
-
Net Income/Loss:
$-31.64M
P/E Ratio:
-4.5906
EPS:
-0.4226
Net Cash Flow:
$-13.98M
1W Performance:
-5.37%
1M Performance:
-6.73%
6M Performance:
-50.38%
1Y Performance:
+0.00%
1-Day Range:
$1.915
$2.01
1-Week Range:
$1.91
$2.10
52-Week Range:
$1.58
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
Compare NGEN vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
1.94 | 208.59M | 0 | -31.64M | -13.98M | -0.4226 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Nervgen Pharma Corp Stock (NGEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | H.C. Wainwright | Buy |
Nervgen Pharma Corp Stock (NGEN) Latest News
NervGen Pharma Corp. (NASDAQ: NGEN) Share Price, NGEN Stock News, NGEN Share Price & Updates - kalkine.ca
NervGen Pharma Corp. (NGEN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
NervGen Pharma (NGEN) Plans Financial Statement Restatements Ami - GuruFocus
NervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results - TipRanks
NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments - marketscreener.com
Nervgen’s RESTORE Trial Moves Toward Launch: What NVG-291 Could Mean for NGEN Investors - TipRanks
NervGen Pharma Appoints KPMG US as New Auditor After Canadian Resignation - TipRanks
NervGen Pharma Corp.(NasdaqCM: NGEN) added to S&P Global BMI Index - marketscreener.com
NervGen Pharma (NASDAQ:NGEN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
What's Going On With NervGen Pharma Corp Stock Thursday? - Wealth Awesome
NervGen to Host Inaugural R&D Day on September 30, 2026 - marketscreener.com
Four experts join a live spinal cord research webcast - Stock Titan
NervGen Pharma (NGEN) Edges Higher to $2.33 as Shares Hold Between Key Support and ResistanceVolatility Term Structure - careplusvn.com
Can NervGen Pharma (TSXV:NGEN) Advance Canada’s Biotech Story? - Kalkine Media
NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates - Barchart.com
NervGen Presents Additional Phase 1 Clinical Trial Data for NVG-291 at Neuroscience 2021 - TMX Newsfile
NervGen Pharma Receives Investment from Drug Manufacturing Partner - TMX Newsfile
NervGen (NGEN) Results Check: The Available Figures Are Largely in Line in the Latest Session; Post-Earnings: Shares Rise 4.30% at the CloseAnnual Report - dars.gov.et
What Makes NervGen Pharma (TSXV:NGEN) A Biotech Watchlist Name? - Kalkine Media
NervGen Pharma (NGEN) Institutional Ownership 2026 - MarketBeat
NervGen (NGEN) Results Check: Available Metrics Are Broadly in Line for the Current Session; Share Response: The Stock Loses 1.14% in Latest TradingEarnings Surprise Score - vinanet.vn
NervGen (NGEN) Earnings Update: Available Metrics Are Broadly Near Expectations in the Latest Reading; Stock Move - vinanet.vn
symbol__ Stock Quote Price and Forecast - CNN
Analysts Are Bullish on Top Healthcare Stocks: Auxly Cannabis Group (CBWTD), Genelux Corp. (GNLX) - The Globe and Mail
NervGen Pharma (NGEN) Advances RESTORE Study with FDA Backing, F - GuruFocus
NervGen Pharma (HAM:9UA) Cyclically Adjusted PS Ratio : (As of Aug. 16, 2026) - GuruFocus
NervGen Pharma (NASDAQ:NGEN) Stock Rating Lowered by Wall Street Zen - MarketBeat
NervGen Pharma (NGEN) Dips 1.4% to $1.74, Holds Above Key SupportAndrews Pitchfork - dars.gov.et
NGEN: RESTORE Phase 3 trial advances with robust funding and FDA alignment; Q2 net loss widens - TradingView
NervGen Pharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
NervGen Q2 FY26 net loss widens to C$29.2 million - Bitget
NervGen Pharma (NGEN) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
NGEN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
NervGen Pharma (NGEN) Q3 2025 Earnings: Narrower-than-Expected Loss as Pipeline Development ContinuesFinancial Summary - careplusvn.com
NervGen Pharma (NGEN) Edges Higher to $1.62, Holding Above Key Support LevelBackspread Trade - vinanet.vn
NGEN Q3 2025 Earnings: Narrower Net Loss Brings a 0.99 Percent Positive SurpriseEarnings Trend Analysis - careplusvn.com
NervGen Pharma (NGEN) Holds Near Support as Price Pullback Tests Key LevelsDemand Zone - dars.gov.et
Oramed Pharmaceuticals Market Sentiment - Benzinga
Nervgen Pharma Ord Shs (NGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Nervgen Pharma Ord Shs (NGEN) Balance Sheet - TradingKey
Nervgen Pharma Ord Shs (NGEN) Institutional Confidence - TradingKey
Nervgen Pharma Ord Shs (NGEN) Income Statement - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.640|Chg%:+0.010 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Nervgen Pharma Ord Shs (NGEN) Cash Flow - TradingKey
NervGen Pharma Corp. Revenue Breakdown – NASDAQ:NGEN - TradingView
Nervgen Pharma Ord Shs (NGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NGEN|Nervgen Pharma Ord Shs|Price:1.630|Chg%:-0.045 - TradingKey
Nervgen Pharma Ord Shs (NGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NGEN Q3 2025 Earnings: Narrower Loss Surprises as Clinical Pipeline Progress ContinuesPre-Earnings Setup - careplusvn.com
Nervgen Pharma Ord Shs (NGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Nervgen Pharma Corp Stock (NGEN) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):